Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

October 20, 2023

Study Completion Date

October 20, 2023

Conditions
Methylmalonic AcidemiaPropionic Acidemia
Interventions
DRUG

HST5040

Liquid solution

DRUG

Placebo

Liquid solution

Trial Locations (16)

3052

Royal Children's Hospital Melbourne, Parkville

11211

King Faisal Specialist Hospital and Research Centre, Riyadh

15213

University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh, Pittsburgh

20010

Children's National Health System, Washington D.C.

30322

Emory University School of Medicine, Atlanta

37232

Vanderbilt University Medical Center, Nashville

43205

Nationwide Children's Hospital, Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

55455

University of Minnesota, Minneapolis

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

64108

Children's Mercy Hospital Kansas City, Kansas City

77030

John P. and Kathrine G. McGovern Medical School, Houston

84132

University of Utah Hospital, Salt Lake City

92123

Rady Children's Hospital, San Diego

06520

Yale, New Haven

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
lead

HemoShear Therapeutics

INDUSTRY

NCT04732429 - Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia | Biotech Hunter | Biotech Hunter